The NLRP3 gene Muckle-Wells Syndrome genetic test is a specialized diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the NLRP3 gene, which are associated with Muckle-Wells Syndrome (MWS). MWS is a rare genetic disorder characterized by recurrent episodes of fever, rash, joint pain, and in some cases, progressive hearing loss and kidney damage. The condition is part of a group of diseases known as cryopyrin-associated periodic syndromes (CAPS), which are caused by mutations in the NLRP3 gene. This gene plays a crucial role in the body's immune response, and mutations can lead to inappropriate inflammation.
The test is aimed at individuals who exhibit symptoms of MWS or have a family history of the condition, providing them with a definitive diagnosis. Early detection through this genetic test is vital for the management of symptoms and prevention of complications associated with MWS. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed for specific mutations in the NLRP3 gene.
DNA Labs UAE offers this comprehensive genetic testing service for a cost of 4400 AED. The test is performed in a state-of-the-art laboratory by experienced geneticists and molecular biologists, ensuring high accuracy and reliability of the results. Once the analysis is complete, a detailed report is provided, offering insights into the patient's genetic makeup concerning the NLRP3 gene. This information is crucial for the development of a personalized treatment plan, which may include medication to control inflammation and prevent damage to organs.
In summary, the NLRP3 gene Muckle-Wells Syndrome genetic test by DNA Labs UAE is a valuable diagnostic tool for individuals suspected of having MWS, offering a path to better disease management and improved quality of life through early and accurate diagnosis.
The MAFB Gene Multicentric Carpotarsal Osteolysis Syndrome Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the MAFB gene, which are linked to multicentric carpotarsal osteolysis syndrome (MCTO). MCTO is a rare genetic disorder characterized by progressive resorption of certain bones in the hands and feet, leading to pain, deformity, and potentially, loss of function. This condition may also be associated with kidney problems in some patients.
The test is crucial for the accurate diagnosis of MCTO, enabling targeted management and intervention strategies for affected individuals. By analyzing a patient's DNA sample, the test can confirm the presence of specific genetic alterations in the MAFB gene that cause the syndrome, providing essential information for families and healthcare providers.
Offered at a cost of 4400 AED, the MAFB Gene Multicentric Carpotarsal Osteolysis Syndrome Genetic Test at DNA Labs UAE represents an important resource for individuals presenting symptoms suggestive of MCTO or those with a family history of the condition, aiming to facilitate early diagnosis and appropriate care planning.
The MMP2 gene multicentric osteolysis nodulosis and arthropathy (MONA) genetic test is a specialized diagnostic tool used to identify mutations in the MMP2 gene, which are linked to the development of MONA. This rare genetic disorder is characterized by progressive bone erosion, nodulosis, and arthropathy, affecting joints and leading to significant morbidity. The test involves analyzing the patient's DNA to detect specific mutations in the MMP2 gene, which provides crucial information for accurate diagnosis, management, and understanding the inheritance pattern of the condition.
The cost of the MMP2 gene MONA genetic test is 4400 AED. The test is conducted at DNA Labs UAE, a leading facility that specializes in advanced genetic testing and analysis. DNA Labs UAE employs state-of-the-art technology and adheres to stringent quality standards, ensuring reliable and precise test results. This test is pivotal for families affected by MONA, as it aids in early diagnosis, enabling timely intervention and potentially improving the quality of life for those diagnosed with this challenging condition.
The CHRNA1 Gene Multiple Pterygium Syndrome Lethal Type Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, aimed at identifying mutations in the CHRNA1 gene, which are associated with the lethal type of Multiple Pterygium Syndrome (LMPS). This rare genetic disorder is characterized by multiple pterygia (webs of skin) across various parts of the body, joint anomalies, facial dysmorphisms, and severe prenatal growth deficiency, often leading to neonatal fatality.
This genetic test is crucial for early and accurate diagnosis, enabling appropriate genetic counseling and management strategies for affected families. The test involves analyzing the patient's DNA to detect mutations in the CHRNA1 gene, which plays a significant role in neuromuscular signaling. Identifying these mutations helps confirm the diagnosis of LMPS lethal type, differentiating it from other forms of the syndrome and related neuromuscular disorders.
The cost of the CHRNA1 Gene Multiple Pterygium Syndrome Lethal Type Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis and detailed reporting necessary for a conclusive diagnosis. The test is conducted in a state-of-the-art facility, ensuring high accuracy and reliability of the results, which are critical for the affected individuals and their families in managing this severe condition.
The CHRND gene multiple pterygium syndrome lethal type genetic test is a sophisticated diagnostic procedure offered by DNA Labs UAE, aimed at identifying mutations in the CHRND gene associated with the lethal type of multiple pterygium syndrome (LMPS). This rare genetic disorder is characterized by the presence of multiple pterygia (webs of skin) across various parts of the body, joint contractures, fetal growth restriction, and other congenital anomalies, often leading to prenatal or neonatal mortality. The CHRND gene plays a crucial role in the development and function of the neuromuscular junction, and mutations in this gene can disrupt normal muscle function, contributing to the syndrome's manifestations.
This genetic test involves analyzing the patient's DNA to detect specific mutations in the CHRND gene that are known to cause the lethal type of multiple pterygium syndrome. It is a critical tool for accurate diagnosis, allowing for appropriate genetic counseling and management of affected families. The test is particularly valuable for prospective parents with a family history of the condition or for cases where fetal abnormalities suggestive of LMPS are detected during pregnancy.
At DNA Labs UAE, the test is priced at 4400 AED, reflecting the specialized nature of the analysis and the expertise required to interpret the results accurately. The cost encompasses the full testing process, from sample collection to detailed reporting. By opting for this test at DNA Labs UAE, patients and their families can expect comprehensive support, from initial consultation through to the delivery of results and beyond, ensuring that they are fully informed and supported throughout the diagnostic journey.
The AAGAB gene is associated with the development of Keratoderma Palmoplantar Punctate Type 1A, a rare genetic skin disorder characterized by the appearance of small, punctate calluses on the palms of the hands and soles of the feet. These skin abnormalities typically emerge during childhood or adolescence and can lead to discomfort or pain, impacting the quality of life. The condition is inherited in an autosomal dominant pattern, meaning a mutation in just one of the two copies of the gene is sufficient to cause the disorder.
A genetic test for Keratoderma Palmoplantar Punctate Type 1A focuses on identifying mutations in the AAGAB gene that are responsible for the condition. This test is crucial for confirming the diagnosis, understanding the inheritance pattern, and providing accurate genetic counseling for affected families. Additionally, it can help in the management and treatment planning of the condition by healthcare professionals.
At DNA Labs UAE, the test for the AAGAB gene mutation associated with Keratoderma Palmoplantar Punctate Type 1A is available for individuals who are suspected to have the condition based on clinical symptoms or have a family history of the disorder. The test cost is set at 4400 AED. DNA Labs UAE is equipped with state-of-the-art technology and staffed by experienced geneticists and laboratory technicians, ensuring accurate and reliable test results. This facility provides a comprehensive service that includes sample collection, DNA analysis, and a detailed report of the findings, along with counseling sessions to discuss the results and implications for the patient and their family.
The "MBTPS2 Gene Keratosis Follicularis Spinulosa Declavans X-Linked Genetic Test" is a specialized diagnostic procedure designed to identify mutations in the MBTPS2 gene, which are linked to the development of Keratosis Follicularis Spinulosa Declavans (KFSD). KFSD is a rare, X-linked genetic disorder characterized by widespread keratosis, follicular hyperkeratosis, and progressive cicatricial alopecia of the scalp. This condition primarily affects males, although female carriers may exhibit milder symptoms.
The test is aimed at individuals who exhibit symptoms of KFSD or have a family history of the disorder, providing crucial information for accurate diagnosis, management, and genetic counseling. Conducted at DNA Labs UAE, a leading facility in genetic testing, the test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing it for specific mutations in the MBTPS2 gene that are known to cause the condition.
The cost of the test is set at 3200 AED, reflecting the comprehensive analysis and detailed reporting provided. Results from this test can help in making informed decisions regarding treatment options and understanding the risk of passing the condition on to future generations. It is a vital tool for affected families and individuals in managing this rare genetic skin disorder.
The "POMP Gene Keratosis Linearis with Ichthyosis Congenita and Sclerosing Keratoderma Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the POMP gene. These mutations are associated with a rare genetic disorder characterized by a combination of skin conditions, including keratosis linearis, ichthyosis congenita, and sclerosing keratoderma. The test aims to provide crucial genetic information that can help in the diagnosis and management of these conditions.
The procedure involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of specific genetic alterations in the POMP gene. This gene plays a significant role in skin development and health, and mutations can lead to the aforementioned complex skin disorders.
The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the valuable insights it offers for affected individuals and their families. By identifying the genetic underpinnings of these conditions, healthcare providers can better understand the disease mechanism, predict its progression, and tailor treatment plans to manage symptoms effectively. DNA Labs UAE, with its state-of-the-art facilities and expertise in genetic diagnostics, ensures high-quality testing and reliable results for patients seeking answers to complex genetic questions.
The DSG1 Gene Keratosis Palmoplantaris Striata Type 1 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to detect mutations in the DSG1 gene, which are linked to the development of Keratosis Palmoplantaris Striata Type 1. This condition, also known as Striate Palmoplantar Keratoderma (SPPK) Type 1, is a rare genetic disorder characterized by the thickening of the skin on the palms of the hands and soles of the feet, often presenting in a linear or striated pattern. The test plays a crucial role in confirming the diagnosis, enabling informed decisions about treatment options, and providing valuable information for family planning. The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the comprehensive insights it offers to affected individuals and their families. Conducted in the state-of-the-art facilities of DNA Labs UAE, this genetic test represents a critical step towards personalized medicine for patients with this rare condition.
The DSP Gene Keratosis Palmoplantaris Striata Type 2 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the DSP gene that are associated with Keratosis Palmoplantaris Striata Type 2. This condition, also known as Striate Palmoplantar Keratoderma Type 2, is a rare genetic disorder characterized by the development of thickened skin on the palms of the hands and the soles of the feet, often presenting in a striated pattern. The test is crucial for individuals who exhibit symptoms of the condition or have a family history of the disorder, as it can confirm the diagnosis and inform potential treatment strategies.
Performed in a state-of-the-art laboratory setting, the test involves analyzing the patient's DNA sample, typically obtained through a blood draw or cheek swab, to detect specific mutations in the DSP gene that are indicative of the disorder. The DSP gene plays a significant role in the development and function of the skin and its structures, making mutations in this gene a key factor in the development of Keratosis Palmoplantaris Striata Type 2.
The cost of the DSP Gene Keratosis Palmoplantaris Striata Type 2 Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the comprehensive nature of the test, including the advanced genetic analysis required to identify the relevant DSP gene mutations. Patients considering this test are advised to consult with a healthcare professional or genetic counselor to discuss the implications of the results and any subsequent steps that should be taken in light of a positive diagnosis.
